New York, USA – July 15, 2026 – The expansion is designed to address recurring bottlenecks in veterinary therapeutic protein and peptide development, including inconsistent early hit quality, long screening cycles, limited species relevance and false-positive signals that can slow hit-to-lead decision-making.
BioVenic’s veterinary biologics discovery workflow includes target identification, assay development, HTS-based hit identification, phage display selection, hit confirmation and lead optimization support. The workflow is built for veterinary therapeutic proteins, peptide candidates and protein binders across diverse animal health applications.
Integrated HTS Workflow Built Around Discovery Questions
Rather than positioning HTS as a stand-alone screening step, BioVenic organizes its assay capabilities around the scientific questions that animal health drug developers need to answer. The platform supports binding characterization, functional activity screening, protein-protein interaction analysis and hit confirmation, helping research teams evaluate both molecular recognition and biological response.
For binding characterization, BioVenic applies analytical approaches such as enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), isothermal titration calorimetry (ITC) and molecular binding assays to assess affinity, specificity and kinetic behavior. For functional activity screening, cell-based assays, enzyme activity assays, gene expression screening and compound library screening can be used to evaluate whether candidate biologics produce relevant biological effects under project-specific conditions.
Protein-protein interaction analysis can be supported through technologies such as co-immunoprecipitation (Co-IP), FRET/BRET and AlphaScreen, while complementary tools including microarray platforms, mass spectrometry and high-content screening help confirm hit identity, activity and assay consistency. This grouped approach allows technical methods to be selected according to the objective of the study rather than listed as disconnected capabilities.
In-House Phage Display Capabilities Support Hit-to-Lead Optimization
BioVenic has also expanded its in-house phage display capabilities to support the discovery and refinement of peptide and protein binders against veterinary disease targets. The workflow can be used for affinity selection, enrichment, binder identification and early optimization, helping improve the quality of candidates entering downstream preclinical evaluation.
When phage display is combined with HTS-based validation, candidate binders can be evaluated through multiple layers of evidence. Phage display selection helps enrich target-binding molecules, while orthogonal screening and confirmation assays help reduce false positives and prioritize candidates with stronger functional and translational rationale.
This integrated hit-to-lead strategy is particularly relevant for animal health drug discovery programs in which target biology, species differences and assay context can strongly influence early development decisions.
Broad Species Coverage for Animal Health and One Health Programs
BioVenic’s platform is designed to support projects involving livestock, poultry, aquaculture species, companion animals and economically important insects. This species coverage is relevant to therapeutic areas such as infectious disease, immune modulation, anti-infective alternatives, vaccine-adjacent biologics, diagnostic binder development and production-performance-related targets.
For veterinary pharmaceutical developers, species relevance is a key consideration during early discovery. A candidate that performs well in a generic assay may still require additional evaluation in a species-appropriate biological context before it can be prioritized for downstream preclinical work. BioVenic’s workflow is therefore structured to connect assay design, target biology and lead-selection criteria from the beginning of a project.
Integrated Design Reduces Technical Transfer Gaps
A central goal of the expanded capability suite is to reduce the friction that can occur when target validation, screening, binder selection and hit confirmation are handled as disconnected activities. By integrating these steps within a single discovery workflow, BioVenic aims to reduce technical transfer delays, improve data continuity and support more confident candidate prioritization.
The approach also enables multi-assay cross-validation. Candidate molecules can be assessed through binding, functional and interaction-based readouts, helping teams distinguish assay artifacts from biologically meaningful hits. For programs with limited internal screening capacity, this can provide a more structured path from exploratory discovery to candidates ready for downstream preclinical evaluation.
“Veterinary biologics discovery requires more than rapid screening,” said a BioVenic representative. “Project teams need assays that reflect the target, the species and the intended biological effect. By combining HTS, phage display and confirmation workflows, we help researchers make earlier and more reliable decisions about which candidates should advance.”
Supporting Next-Generation Veterinary Biologics Development
As animal health pipelines expand beyond conventional small molecules and vaccines, demand is increasing for discovery systems that can support therapeutic proteins, peptides and protein binders with clearer translational logic. BioVenic’s expanded platform is intended to support this shift by combining scalable screening, binder discovery and lead optimization planning for preclinical veterinary biologics services.
Researchers, biotech developers and veterinary pharmaceutical partners can contact BioVenic’s scientific team to discuss target-specific assay design, HTS workflow development, phage display screening strategy or veterinary biologics lead optimization projects.
About BioVenic
BioVenic is a veterinary biotechnology company focused on enabling therapeutic protein and peptide discovery for the global animal health and life sciences industries. The company provides integrated preclinical discovery solutions designed to support target identification, screening, binder discovery, hit confirmation and lead optimization for veterinary biologics development.
Visit https://www.biovenic.com to learn more.
Media Contact
Company Name: BioVenic
Contact Person: Ashley Hutt
Email: Send Email
Phone: 1-631-593-0561
Country: United States
Website: https://www.biovenic.com
